Street forms of synthetic cannabinoids - so-called "synthetic marijuana" - were linked to 11,406 of the 4.9 million drug-related emergency department (ED) visits in 2010, according to a new report by the Substance Abuse and Mental Health Services Administration (SAMHSA).
Commonly known by such street names as "K2" or "Spice," synthetic cannabinoids are substances that are not derived from the marijuana plant but purport to have the same effect as the drug. Though an increasing number of states have passed laws against the sale of synthetic cannabinoids, they have been marketed as a "legal" alternative to marijuana during the past few years. In July 2012, a comprehensive, national ban was enacted against the sale of synthetic cannabinoids under Title XI of the Food and Drug Administration Safety and Innovation Act.
Today's report points out that the use of synthetic cannabinoids is tied to a variety of reported symptoms including agitation, nausea, vomiting, tachycardia (rapid heartbeat), elevated blood pressure, tremor, seizures, hallucinations, paranoid behavior and non-responsiveness.
The report found that youths between the ages of 12 to 29 constituted 75 percent of all hospital ED visits involving synthetic cannabinoids, with males accounted for 78 percent of the ED admissions among this age group. The average age for people involved in synthetic cannabinoid-related ED admissions was younger than for marijuana-related ED visits (24 years old versus 30 years old).